Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, Fowler VG Jr, Chu VH, Spencer E, Barriere SL, Kitt MM, Cabell CH, Corey GR; FAST Investigator Group.
Stryjewski ME, et al. Among authors: cabell ch.
Clin Infect Dis. 2005 Jun 1;40(11):1601-7. doi: 10.1086/429914. Epub 2005 Apr 28.
Clin Infect Dis. 2005.
PMID: 15889357
Clinical Trial.